ArticleEndocrine2013
Everolimus therapy for progressive adrenocortical cancer.
Article in Endocrine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.Clinical Medicine Insights. Oncology · 2025Review
- Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options.Cancers · 2022Article
- Review
- Review
- The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.Biomedicines · 2021Review
- Management of adrenocortical carcinoma: are we making progress?Therapeutic advances in medical oncology · 2021Review
- Review
- IGF2 role in adrenocortical carcinoma biology.Endocrine · 2019Article
- The role of mTOR pathway as target for treatment in adrenocortical cancer.Endocrine connections · 2019Review
- The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.Cancer cell international · 2018Article
- Article
- P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model.Oncogene · 2017Article
- Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.Endocrine pathology · 2017Article
- Review
- Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.Endocrine · 2016Article
- Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the Literature.World journal of oncology · 2015Article
- MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.Cellular and molecular life sciences : CMLS · 2015Review
- Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.Endocrine pathology · 2014Review
- Adrenocortical carcinoma: the management of metastatic disease.Critical reviews in oncology/hematology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with advanced adrenocortical carcinoma (ACC) have limited treatment options after failure of chemotherapy. Tumor IGF2 expression has been shown to be amplified in the majority of cases of ACC and autocrine/paracrine activation of the IGF receptor (IGF-R) is thought to play a major role in the pathogenesis of ACC. It has been shown in vitro that inhibition of the IGF-R inhibits ACC cell proliferation. mTOR is a downstream effector of the IGFR signaling pathway; therefore, the rapamycin analog everolimus could prove to be useful for treatment of patients with ACC. Four women with ACC (ages 25-60 years) developed stage IV disease after surgery. All had progressive disease (PD) despite treatment with mitotane and other treatment modalities (etoposide, doxorubicin, cis-platinum in 3/4 patients, further streptozotocin + 5-FU in 1/4 patients, further thalidomide therapy in 2/4 patients; 1 patient progressed on an IGF-R antagonist). The patients were started on everolimus 10 mg/day orally and 2/4 patients also continued mitotane. Disease progression was monitored monthly by CT in 3/4 and after 3 months in 1/4. In all patients everolimus was well tolerated. In the three patients monitored monthly, PD was evident after 1, 3, and 4 months; in the patient evaluated after 3 months PD was also evident. In this small exploratory study, no clinically meaningful response was observed with everolimus in four patients with advanced ACC. The failure of efficacy could be related to an interaction with mitotane, multiple signaling pathways, and/or other downstream IGF-R effectors operative in the pathogenesis of ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.